- Location
Mylan pharmaceuticals
"-
Initiation of Secure Supply Chain Pilot Program to Enhance The Security of Imported Drugs
Feb 19, 2014The U.S. Food and Drug Administration is announcing the initiation of the Secure Supply Chain Pilot Program to enhance the security of imported drugs. In August 2013, the FDA published a notice in the Federal Register (78 FR 51192) to ...
-
Mylan Announced That Its U.S. Has Launched Mycophenolic Acid Delayed-Release Tablets
Jan 10, 2014Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg. This product is the generic version of Novartis' Myfortic® ...
-
Mylan Today Announced That Subsidiary Mylan Pharmaceuticals and Partner,Banner Pharmacaps
Dec 19, 2013Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. ...
Tags: Mylan, Targretin Suit, Treatment of Cutaneous Manifestations
-
INSV Has Reported The US District Court Upheld All Four of The Patents Protecting AzaSite
Oct 10, 2013InSite Vision Incorporated (INSV) has reported that the US District Court for the District of New Jersey upheld all four of the patents protecting AzaSite, an azithromycin 1% ophthalmic solution, in a patent infringement lawsuit against ...
-
Mylan Pharmaceuticals Has Introduced Voriconazole for Oral Suspension
Oct 8, 2013Mylan Pharmaceuticals, a subsidiary of Mylan, has introduced Voriconazole for oral suspension, 40 mg/mL, which is the first generic version of Pfizer's VFEND for oral suspension. The US Food and Drug Administration (FDA) has granted a ...
Tags: Mylan, Antifungal Drug
-
MeadWestvaco Corp. Introduced Shellpak Renew with OptilockT Technology.
Aug 8, 2013MeadWestvaco Corp. (MWV), a global leader in packaging and packaging solutions, introduced Shellpak Renew with OptilockT technology. This smaller, more discreet medication adherence package is designed to meet patient and pharmacist needs ...
Tags: Packaging
-
Mylan Pharmaceuticals and Orion Have Entered Into a Settlement and License Agreement
Jul 26, 2013Mylan Pharmaceuticals and Orion have entered into a settlement and license agreement, which dismisses the parties pending litigation related to Mylan's filing of an Abbreviated New Drug Application (ANDA) with the US FDA for the generic ...
Tags: Mylan, Orion, Generic Version
-
Mylan Pharmaceuticals Has Introduced Norethindrone for The Prevention of Pregnancy in US
Jul 18, 2013Mylan Pharmaceuticals has introduced Norethindrone Tablets USP, 0.35mg, which is the generic version of Watson Laboratories' (now Actavis) Nor-Q.D. tablets, 0.35mg for 28-day cycle, for the prevention of pregnancy in the US. The ...
Tags: Generic Contraceptive Pill, Mylan
-
Mylan Pharmaceuticals Has Launched The First Generic Versions of Abbott's Trilipix Capsule
Jul 17, 2013Mylan Pharmaceuticals, Mylan's US subsidiary, has launched one of the first generic versions of Abbott's Trilipix Capsule in the US. Known as Fenofibric Acid Delayed-release Capsules, 45mg and 135mg is indicated for patients with mixed ...
-
Mylan Pharmaceuticals Has Introduced a Portfolio of Women's Healthcare Products in India
Jun 28, 2013Generic and specialty pharmaceutical company Mylan Pharmaceuticals has introduced a portfolio of women's healthcare products in India, expanding its product base in the country. Consisting of eight products initially, the portfolio is ...
Tags: Women's Care Products, Medicine
-
Mylan Pharmaceuticals Has Introduced Generic Equivalent to Micronor Tablets
Jun 28, 2013US-based Mylan Pharmaceuticals has introduced generic equivalent to Micronor tablets, 0.35mg (28-day cycle) indicated for the prevention of pregnancy in the US. Norethindrone Tablets USP, 0.35mg, are the generic version of Janssen ...
Tags: Generic Micronor Tablets, Medicine
-
Mylan Pharmaceuticals Has Introduced Fenofibrate Tablets, 48 Mg and 145 Mg
May 22, 2013Mylan Pharmaceuticals, the subsidiary of Mylan, has introduced Fenofibrate tablets, 48 mg and 145 mg. The company has received the final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application ...
Tags: Mylan, Generic Version
-
US FDA Has Approved Mylan Pharmaceuticals' ANDA for Zolmitriptan Tablets, 2.5mg and 5mg.
May 17, 2013The US FDA has approved Mylan Pharmaceuticals' abbreviated new drug application (ANDA) for Zolmitriptan tablets, 2.5mg and 5mg. The generic equivalent of IPR Pharmaceuticals' Zomig tablets is indicated for the acute treatment of migraine ...
Tags: FDA, Pharmaceuticals
-
The US FDA Has Granted Final Approval for Mylan Pharmaceuticals' ANDA
Apr 4, 2013The US FDA has granted final approval for Mylan Pharmaceuticals' abbreviated new drug application (ANDA) for Acyclovir Ointment USP, 5%. Acyclovir Ointment is the generic equivalent to Zovirax Ointment from Valeant International. Mylan ...
Tags: FDA, Acyclovir Ointment, Medicine
-
Mylan Pharmaceuticals Has Launched Fenofibrate Capsules USP,43 Mg and 130 Mg.
Feb 27, 2013Mylan Pharmaceuticals, a subsidiary of global pharmaceutical company Mylan, has launched Fenofibrate Capsules USP, 43 mg and 130 mg. Fenofibrate Capsules, which are generic equivalent to Lupin Atlantis Holdings' Antara Capsules, are ...
Tags: Mylan Pharmaceuticals, Fenofibrate Capsules, pharmaceutical company
